← 홈

Antibody

74개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 74개
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab with dexamethasone)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 18.4%임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab, Ixazomib, Dexamethasone)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 3

daratumumab (Darzalex, Daratumumab/Lenalidomide/Dexamethasone for 24 months)

Multiple Myeloma in Relapse · Multiple Myeloma in Relapse

#MultipleMyelomainRelapse#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 3

daratumumab (Darzalex, Daratumumab/Lenalidomide/Dexamethasone until progression)

Multiple Myeloma in Relapse · Multiple Myeloma in Relapse

#MultipleMyelomainRelapse#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab/rHuPH20 Co-formulation)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 3

Daratumumab (Darzalex Faspro, Darzalex Faspro(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 3

daratumumab (Darzalex, Early treatment of relapse with carfilzomib, dexamethasone, daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystalePfizerPhase 2

Elranatamab + Nirogacestat (Elranatamab + Nirogacestat)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleWashington University School of…Phase 2

Elrantamab (Elrantamab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Ixazomib and Daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleJanssenPhase 1

Daratumumab (JNJ-54767414, JNJ-54767414 (Daratumumab))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAbbViePhase 1

Lemzoparlimab (Lemzoparlimab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleHospital Universitario Dr. Jose…Phase 2

Low-dose teclistamab (Low-dose teclistamab)

Multiple Myeloma, Newly Diagnosed · Multiple Myeloma, Newly Diagnosed

#MultipleMyelomaNewlyDiagnosed#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystalePfizerPhase 1

Maplirpacept (Maplirpacept)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystalePfizerPhase 1

PF-07901801 (Maplirpacept, Maplirpacept (PF-07901801))

Lymphoma; Multiple Myeloma · Lymphoma

#Lymphoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Part 1, Dose Escalation, Part 1 (Dose Escalation): Daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
효능 ORR 81.3%임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Part 1: Daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
효능 ORR 33.3%임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Part 2, Dose Expansion, Part 2 (Dose Expansion): Daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
효능 ORR 81.3%임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Part 2: Daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
효능 ORR 33.3%임상시험 1상태 ACTIVE

3 / 4 페이지

← 이전다음 →